We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Reaches Deal With Novo Nordisk Over Victoza Patent
Teva Reaches Deal With Novo Nordisk Over Victoza Patent
Teva Pharmaceuticals has agreed to a patent litigation settlement with Novo Nordisk that would see the generic drugmaker wait until December 2023 to begin marketing its generic version of the type 2 diabetes drug Victoza (liraglutide).